AngioDynamics, Inc. (ANGO)
ANGO Stock Price Chart
Explore AngioDynamics, Inc. interactive price chart. Choose custom timeframes to analyze ANGO price movements and trends.
ANGO Company Profile
Discover essential business fundamentals and corporate details for AngioDynamics, Inc. (ANGO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Instruments & Supplies
IPO Date
1 Jun 2004
Employees
748.00
Website
https://www.angiodynamics.comCEO
James C. Clemmer
Description
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.
ANGO Financial Timeline
Browse a chronological timeline of AngioDynamics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 1 Oct 2026
EPS estimate is -$0.09, while revenue estimate is $80.50m.
Earnings released on 14 Jul 2026
EPS came in at -$0.07 surpassing the estimated -$0.11 by +36.36%, while revenue for the quarter reached $86.61m , beating expectations by +7.93%.
Earnings released on 2 Apr 2026
EPS came in at -$0.07 surpassing the estimated -$0.11 by +36.36%, while revenue for the quarter reached $78.42m , beating expectations by +2.16%.
Earnings released on 6 Jan 2026
EPS came in at -$0.15 falling short of the estimated -$0.10 by -50.00%, while revenue for the quarter reached $79.43m , beating expectations by +3.92%.
Earnings released on 2 Oct 2025
EPS came in at -$0.10 surpassing the estimated -$0.14 by +28.57%, while revenue for the quarter reached $75.71m , missing expectations by -0.79%.
Earnings released on 15 Jul 2025
EPS came in at -$0.03 surpassing the estimated -$0.13 by +76.92%, while revenue for the quarter reached $80.16m , beating expectations by +7.95%.
Earnings released on 2 Apr 2025
EPS came in at $0.03 surpassing the estimated -$0.13 by +123.08%, while revenue for the quarter reached $72.00m , missing expectations by -3.03%.
Earnings released on 8 Jan 2025
EPS came in at -$0.04 surpassing the estimated -$0.11 by +63.64%, while revenue for the quarter reached $72.85m , beating expectations by +3.23%.
Earnings released on 3 Oct 2024
EPS came in at -$0.11 surpassing the estimated -$0.15 by +26.67%, while revenue for the quarter reached $67.49m , missing expectations by -0.65%.
Earnings released on 16 Jul 2024
EPS came in at -$0.06 surpassing the estimated -$0.20 by +70.00%, while revenue for the quarter reached $70.98m , beating expectations by +0.18%.
Earnings released on 4 Apr 2024
EPS came in at -$0.16 falling short of the estimated -$0.14 by -14.29%, while revenue for the quarter reached $75.18m , missing expectations by -0.72%.
Earnings released on 5 Jan 2024
EPS came in at -$0.05 surpassing the estimated -$0.09 by +44.44%, while revenue for the quarter reached $79.07m , missing expectations by -3.62%.
Earnings released on 4 Oct 2023
EPS came in at -$0.12 surpassing the estimated -$0.14 by +14.29%, while revenue for the quarter reached $78.68m , beating expectations by +1.27%.
Earnings released on 12 Jul 2023
EPS came in at $0.02 falling short of the estimated $0.02 by -11.11%, while revenue for the quarter reached $91.07m , beating expectations by +0.38%.
Earnings released on 30 Mar 2023
EPS came in at -$0.03 falling short of the estimated -$0.01 by -300.00%, while revenue for the quarter reached $80.71m , missing expectations by -11.46%.
Earnings released on 5 Jan 2023
EPS came in at $0.01 surpassing the estimated $0.00 by +200.30%, while revenue for the quarter reached $85.43m , beating expectations by +1.24%.
Earnings released on 6 Oct 2022
EPS came in at -$0.06 falling short of the estimated -$0.02 by -166.67%, while revenue for the quarter reached $81.54m , missing expectations by -2.27%.
Earnings released on 12 Jul 2022
EPS came in at $0.01 surpassing the estimated $0.01 by +33.33%, while revenue for the quarter reached $87.00m , beating expectations by +4.92%.
Earnings released on 7 Apr 2022
EPS came in at $0.03 surpassing the estimated $0.01 by +339.88%, while revenue for the quarter reached $73.97m , missing expectations by -3.08%.
Earnings released on 6 Jan 2022
EPS came in at -$0.02 falling short of the estimated -$0.00 by -481.40%, while revenue for the quarter reached $78.28m , beating expectations by +2.57%.
Earnings released on 30 Sept 2021
EPS came in at -$0.02 surpassing the estimated -$0.05 by +60.00%, while revenue for the quarter reached $76.97m , beating expectations by +7.94%.
ANGO Stock Performance
Access detailed ANGO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
